Trump Signs Order to Boost Research on Psychedelic Treatments for Mental Health

Want the full story?
Read the complete article at KVIA
AI Summary
President Donald Trump has signed an executive order to promote research into psychedelic drugs, particularly ibogaine, as potential treatments for severe mental health issues. The federal government will invest $50 million to expedite research, aiming to address the mental health crisis affecting veterans and others. Trump humorously expressed interest in trying ibogaine himself, while Health and Human Services Secretary Robert F. Kennedy Jr. emphasized the need for faster approval processes for these therapies. Although initial studies show promise, experts warn about the risks associated with psychedelics and the need for rigorous research standards.
Key Details: • Executive order signed to enhance research on psychedelics, especially ibogaine. • $50 million allocated for research funding. • FDA approval timeline for psychedelic treatments could be reduced to weeks. • Ibogaine is currently classified as a Schedule I substance with potential risks.